MindMed doses first subject in trial of tablets for generalized anxiety disorder

cafead

Administrator
Staff member
  • cafead   Dec 17, 2024 at 12:12: PM
via US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of MM120 orally disintegrating tablets (MM120 ODT) for the treatment of generalized anxiety disorder (GAD).

article source